| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
37,110,000 |
| Market
Cap: |
105.76(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.79 - $8.35 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Akoya Biosciences is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. Spatial biology is an evolving technology that enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler™ and PhenoImager™ platforms, reagents, software and services, Co. provides solutions to perform tissue analysis and spatial phenotyping across the continuum from discovery through translational and clinical research.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,423,388 |
2,423,388 |
| Total Buy Value |
$0 |
$0 |
$12,108,954 |
$12,108,954 |
| Total People Bought |
0 |
0 |
7 |
7 |
| Total Buy Transactions |
0 |
0 |
7 |
7 |
| Total Shares Sold |
22,500 |
45,000 |
50,000 |
228,869 |
| Total Sell Value |
$111,321 |
$209,659 |
$238,196 |
$2,534,940 |
| Total People Sold |
1 |
1 |
1 |
4 |
| Total Sell Transactions |
3 |
6 |
7 |
23 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mckelligon Brian |
President and CEO |
• • – |
2023-11-20 |
4 |
AS |
$4.39 |
$32,901 |
D/D |
(7,500) |
152,563 |
|
0% |
|
| Mckelligon Brian |
President and CEO |
• • – |
2023-11-20 |
4 |
OE |
$0.30 |
$2,273 |
D/D |
7,500 |
160,063 |
|
- |
|
| Pla Frederic |
Chief Operating Officer |
• – – |
2023-11-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
70,555 |
|
- |
|
| Kamocsay Jennifer |
General Counsel |
• – – |
2023-11-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
67,500 |
|
- |
|
| Pla Frederic |
Chief Operating Officer |
• – – |
2023-09-07 |
4 |
B |
$4.60 |
$92,014 |
I/I |
20,000 |
20,000 |
1.99 |
9% |
|
| Raffin Thomas A. |
Director |
– • – |
2023-06-12 |
4 |
B |
$5.00 |
$10,100,000 |
I/I |
2,020,000 |
15,937,535 |
2.1 |
-30% |
|
| Mendel Scott |
Director |
– • – |
2023-06-12 |
4 |
B |
$5.00 |
$100,000 |
D/D |
20,000 |
28,500 |
2.39 |
-30% |
|
| Lai Goldman Myla |
Director |
– • – |
2023-06-12 |
4 |
B |
$5.00 |
$100,000 |
D/D |
20,000 |
20,000 |
2.39 |
-30% |
|
| Ek John Frederick |
CFO |
• – – |
2023-06-12 |
4 |
B |
$5.00 |
$100,000 |
I/I |
20,000 |
20,000 |
1.99 |
-30% |
|
| Winkler Matthew |
Director |
– • – |
2023-06-12 |
4 |
B |
$5.00 |
$1,016,940 |
D/D |
203,388 |
984,513 |
2.39 |
-30% |
|
| Shepler Robert G |
Director |
– • – |
2023-06-12 |
4 |
B |
$5.00 |
$600,000 |
I/I |
120,000 |
369,592 |
2.1 |
-30% |
|
| Mckelligon Brian |
President/CEO |
• • – |
2023-06-06 |
4 |
AS |
$5.71 |
$28,537 |
D/D |
(5,000) |
152,563 |
|
-37% |
|
| Mckelligon Brian |
President/CEO |
• • – |
2023-06-06 |
4 |
OE |
$0.30 |
$1,515 |
D/D |
5,000 |
157,563 |
|
- |
|
| Ramachandran Niro Ph.d |
Chief Business Officer |
• – – |
2023-03-23 |
4 |
D |
$7.69 |
$14,957 |
D/D |
(1,945) |
177,235 |
|
- |
|
| Pla Frederic |
Chief Operating Officer |
• – – |
2023-03-23 |
4 |
D |
$7.69 |
$14,957 |
D/D |
(1,945) |
40,555 |
|
- |
|
| Mckelligon Brian |
President/CEO |
• • – |
2023-03-23 |
4 |
D |
$7.69 |
$57,191 |
D/D |
(7,437) |
152,563 |
|
- |
|
| Ek John Frederick |
CFO |
• – – |
2023-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
160,000 |
|
- |
|
| Kamocsay Jennifer |
General Counsel |
• – – |
2023-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
|
- |
|
| Mckelligon Brian |
President/CEO |
• • – |
2023-03-14 |
4 |
AS |
$9.14 |
$45,852 |
D/D |
(5,000) |
160,000 |
|
-23% |
|
| Mckelligon Brian |
President/CEO |
• • – |
2023-03-14 |
4 |
OE |
$0.30 |
$1,515 |
D/D |
5,000 |
165,000 |
|
- |
|
| El-Gabry Ehab |
Chief Medical Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
16,250 |
|
- |
|
| Mckelligon Brian |
President/CEO |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
160,000 |
|
- |
|
| Pla Frederic |
Chief Operating Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
42,500 |
|
- |
|
| Ramachandran Niro Ph.d |
Chief Business Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
179,180 |
|
- |
|
| Moy Marilee |
CHIEF PEOPLE OFFICER |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
87 Records found
|
|
Page 2 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (1.72%) 
